Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-92.72%
0%
-92.72%
6 Months
-94.6%
0%
-94.6%
1 Year
-93.39%
0%
-93.39%
2 Years
-97.48%
0%
-97.48%
3 Years
-99.21%
0%
-99.21%
4 Years
-99.44%
0%
-99.44%
5 Years
-98.02%
0%
-98.02%
Oncimmune Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
28.98%
EBIT Growth (5y)
10.21%
EBIT to Interest (avg)
-6.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.78
Sales to Capital Employed (avg)
0.39
Tax Ratio
12.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.53
EV to EBIT
-1.72
EV to EBITDA
-1.87
EV to Capital Employed
2.96
EV to Sales
2.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-171.87%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2021
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 3 Foreign Institutions (8.25%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Aug'23
Aug'23
Aug'22
Change(%)
Net Sales
1.20
2.30
-47.83%
Operating Profit (PBDIT) excl Other Income
-4.00
-6.10
34.43%
Interest
2.00
0.30
566.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.20
-6.80
8.82%
Operating Profit Margin (Excl OI)
-3,682.30%
-2,717.20%
-96.51%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
About Oncimmune Holdings Plc 
Oncimmune Holdings Plc
Biotechnology
Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.
Company Coordinates 
Company Details
MediCity, D6 Building, 1 Thane Road , NOTTINGHAM None : NG90 6BH
Registrar Details






